Very Simply:

1- We have done our Due Diligence. Up, Down, and sideways. That includes, viability, safety, product portfolio, finances, competitors, history and Intellectual property as represented by GNBT's global patent portfolio.

2- We understand the trend in Biopharma stocks at GNBT's current stage.

3- We understand the investor sentiment trends, both for individuals and analysts (who are always late to the party).

4- We understand The propaganda surrounding other companies and the undeclared war to keep GNBT from being First-To-Market (this time around as well).

5- We understand the true potential for market share both short and long term.

6- We understand the developments and changes within the FDA and how that relates to GNBT.

7- We know how to evaluate GNBT's management and their decisions so far, including how women CEOs differ from men.

Some of us have a more detailed analysis based on information and experience that others most likely don't have, yet we still share parts of it with the general audience because we too had mentors.